Related Experiment Video

Updated: Oct 5, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Anticonvulsant efficacy of gabapentin on kindling in the immature brain

F A Lado1, E F Sperber, S L Moshé

  • 1Department of Neurology, Albert Einstein College of Medicine, Montefiore Medical Center Epilepsy Management Center, Bronx, NY 10461, USA. ladof@ix.netcom.com

Epilepsia
|July 7, 2001
PubMed

Insights

Gabapentin (GBP) shows anticonvulsant effects in young rats at low doses. Higher doses impair motor performance, but therapeutic potential exists for seizure control in immature animals.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Developmental Biology

Background:

  • Epilepsy is a common neurological disorder characterized by recurrent seizures.
  • Gabapentin (GBP) is an anticonvulsant medication used to treat epilepsy and neuropathic pain.
  • The efficacy and safety of GBP in immature animal models require further investigation.

Purpose of the Study:

  • To evaluate the anticonvulsant and motor effects of gabapentin (GBP) in 16-17-day-old rat pups.
  • To determine the effective dose range of GBP for preventing kindled seizures in immature rats.
  • To assess the potential for motor impairment associated with GBP treatment in this age group.

Main Methods:

  • Kindled seizures were induced in 14-day-old rat pups via amygdala electrical stimulation.
  • On day 17, pups received varying doses of GBP (10, 25, 50, or 100 mg/kg).
  • Seizure prevention was assessed by electrical stimulation post-GBP administration.
  • Motor performance was evaluated using a balance beam test in a separate group of rats.

Main Results:

  • Gabapentin demonstrated anticonvulsant effects at doses as low as 10 mg/kg.
  • Motor performance impairment was observed at doses of 50 mg/kg and above.
  • GBP effectively prevented kindled seizures at doses that did not significantly affect motor function.

Conclusions:

  • Gabapentin exhibits significant anticonvulsant properties in immature rats.
  • The therapeutic window for GBP in young animals allows for seizure control without substantial motor deficits.
  • These findings suggest gabapentin's potential as a treatment for seizures in developing individuals.

More Related Videos

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...